Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?
Related Questions
Would you consider adjuvant osimertinib for patients with non-classical but sensitizing EGFR mutation positive NSCLC s/p surgical resection?
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?
What are your top takeaways in Thoracic Cancers from ASCO 2023?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
For patients with metastatic thymic carcinoma, is there a role for local treatment options such as SBRT for oligoprogressive or oligopersistent disease after systemic therapy?
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
What initial therapy do you offer elderly patients with metastatic NSCLC with MET amplification and PD-L1 >50%?
Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
